Augmented acid alpha-glucosidase for the treatment of Pompe disease
US10857212B2 · kind B2 · utility
7Cited by
49References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2018 |
| Grant date | Dec 8, 2020 |
| Priority date | — |
| Expiry date | Nov 23, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/0102
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating Pompe disease including administration of recombinant human acid α-glucosidase having optimal glycosylation with mannose-6-phosphate residues in combination with an amount of miglustat effective to maximize tissue uptake of recombinant human acid α-glucosidase while minimizing inhibition of the enzymatic activity of the recombinant human acid α-glucosidase is provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.